Treatment with the PI3K/ CK1ε inhibitor umbralisib showed fewer immune-mediated adverse reactions compared to PI3K inhibitor therapy H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE TAMPA, Fla. — Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. One in four new leukemia cases are CLL. Early-stage CLL patients often do not require therapy,...
Tag: <span>inhibitors</span>
Post
A chemical tailor-made suit for Alzheimer’s drugs
Research team from Göttingen and Halle develops new inhibitors for enzymes PROTEIN CRYSTALS OF THE HUMAN ENZYME GLUTAMINYL CYCLASE AND ATOMIC STRUCTURE OF THE NEW INHIBITOR. view more CREDIT: LISA-MARIE FUNK With over 1.2 million people affected in Germany alone and over 50 million people worldwide, Alzheimer’s disease, also referred to simply as Alzheimer’s, is...
Post
Study reveals antiviral effects of curcumin
Reviewed by James Ives, M.Psych. (Editor) Curcumin, a natural compound found in the spice turmeric, could help eliminate certain viruses, research has found. A study published in the Journal of General Virology showed that curcumin can prevent Transmissible gastroenteritis virus (TGEV) – an alpha-group coronavirus that infects pigs – from infecting cells. At higher doses,...
Post
Researchers discover potential treatment for rare degenerative disease
by Yale University Yale pharmacology professor Barbara Ehrlich and her team have uncovered a mechanism driving a rare, lethal disease called Wolfram Syndrome and also a potential treatment. Their findings appear in the July 6 edition of Proceedings of the National Academy of Sciences. Wolfram Syndrome—a progressive degenerative disease that affects about one in 500,000...
Post
Mirror image tumor treatment
Checkpoint blockade by a D-peptide for cancer immunotherapy or example, they induce the so-called immune checkpoints of T-cells to shut down immune responses. In the journal Angewandte Chemie, scientists have now introduced a new approach for immunological tumor treatment. Their method is based on the specific blockade of an immune checkpoint by a stable “mirror-image”...
Post
Compounds halt SARS-CoV-2 replication by targeting key viral enzyme
by University of South Florida Three configurations of active sites where inhibitor GC-376 binds with the COVID-19 virus’s main protease (drug target Mpro), as depicted by 3D computer modeling. Credit: Image generated by Yu Chen, University of South Florida Health, using X-ray crystallography As the death toll from the COVID-19 pandemic mounts, scientists worldwide continue...
Post
Common hypertension medications may reduce colorectal cancer risk
Hypertension Journal Report AMERICAN HEART ASSOCIATION DALLAS, July 6, 2020 — Medications commonly prescribed to treat high blood pressure may also reduce patients’ colorectal cancer risk, according to new research published today in Hypertension, an American Heart Association journal. Angiotensin converting enzyme inhibitor (ACE-i) or angiotensin II receptor blocker (ARB) medications are prescribed for conditions...
Post
Nuclear Softening Allows Cells to Move Into Dense Tissue, Encouraging Injury Repair
Using an enzyme inhibitor in meniscus cells, a Penn team was able to soften their nucleus and promote access to previously impassible areas. By softening a cell’s nucleus so that it can squeeze its way through dense connective tissues, a group of researchers believes they’ve demonstrated a new way to help the body efficiently repair...
Post
BALDNESS MAY BE A RISK FACTOR FOR COVID-19
Two small studies published recently suggested most men hospitalized with Covid-19 are bald, generating headlines around the world. While this may sound strange, science does offer a plausible explanation. Male pattern baldness is associated with high levels of male sex hormones called androgens. And androgens seem to play an important role in the entry of...
Post
The New JAK inhibitor Upadacitinib (Rinvoq) Shows Promise for Psoriatic Arthritis
Approved in 2019 for moderate to severe rheumatoid arthritis, the drug may offer an oral alternative to infused or injected biologics. The JAK inhibitor upadacitinib (Rinvoq) became a treatment option in 2019 for people with rheumatoid arthritis(RA) who had not responded well to methotrexate, the disease-modifying anti-rheumatic drug (DMARD) that is the first-line treatment for...